Treatment of terminal peritoneal carcinomatosis by a transducible p53-activating peptide

PLoS Biology

Volumn 2, Issue 2, 2004, Pages

  Snyder, Eric L ^a,b   Meade, Bryan R ^c   Saenz, Cheryl C ^a,d   Dowdy, Steven F ^a,c  

^a HOWARD HUGHES MEDICAL INSTITUTE   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PEPTIDE DERIVATIVE; PROTEIN P53; ANTINEOPLASTIC AGENT; PEPTIDE; RETRO INVERSO TATP53C' PEPTIDE; RETRO-INVERSO-TATP53C' PEPTIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL; CARCINOMATOSIS; CONTROLLED STUDY; DRUG EFFECT; HUMAN; HUMAN CELL; LIFESPAN; LYMPHOMA; MOUSE; NONHUMAN; TREATMENT OUTCOME; CELL DIVISION; GENE EXPRESSION REGULATION; GENE THERAPY; GENETICS; METABOLISM; PATHOLOGY; PERITONEUM TUMOR; PROTEIN PROCESSING; TRANSACTIVATION; TUMOR SUPPRESSOR GENE;

ANIMALIA;

ANTINEOPLASTIC AGENTS; CELL DIVISION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE THERAPY; GENES, P53; HUMANS; PEPTIDES; PERITONEAL NEOPLASMS; PROTEIN PROCESSING, POST-TRANSLATIONAL; TRANS-ACTIVATION (GENETICS); TUMOR SUPPRESSOR PROTEIN P53;

EID: 19344365470     PISSN: 15449173     EISSN: None     Source Type: Journal    
DOI: 10.1371/journal.pbio.0020036     Document Type: Article

References (32)

1. Apella E, Anderson CW (2001) Post-translational modifications and activation of p53 by genotoxic stresses. Eur J Biochem 268: 2764-2772. Find this article online
2. Bertolini F, Fusetti L, Mancuso P, Gobbi A, Corsini C, et al. (2000) Endostatin, an antiangiogenic drug, induces tumor stabilization after chemotherapy or anti-CD20 therapy in a NOD/SCID mouse model of human high-grade non-Hodgkin lymphoma. Neoplasia 96: 282-287. Find this article online
3. Bunz F, Dutriaux A, Lengauer C, Waldman T, Zhou S, et al. (1998) Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science 282: 1497-1501. Find this article online
4. Bykov VJN, Issaeva N, Shilov A, Hultcrantz M, Pugacheva E, et al. (2002) Restoration of tumor suppressor function to mutant p53 by a low-molecular weight compound. Nat Med 8: 282-288. Find this article online
5. Chorev M, Goodman M (1993) A dozen years of retro-inverso peptidomimetics. Acc Chem Res 26: 266-273. Find this article online
6. Datta K, Sundberg C, Karumanchi SA, Mukhopadhyay D (2001) The 104-123 amino acid sequence of the beta-domain of von Hippel-Lindau gene product is sufficient to inhibit renal tumor growth and invasion. Cancer Res 61: 1768-1775. Find this article online
7. de Menezes DEL, Pilarski LM, Allen TM (1998) In vitro and in vivo targeting of immunoliposomal doxorubicin to human B-cell lymphoma. Cancer Res 58: 3320-3330. Find this article online
8. Deppe G, Baumann P (2000) Advances in ovarian cancer chemotherapy. Curr Opin Oncol 12: 481-491. Find this article online
9. Fidler IJ (2003) The pathogenesis of cancer metastasis: The 'seed and soil' hypothesis revisited. Nat Rev Cancer 3: 1-6. Find this article online
10. Fischer P, Krausz E, Lane DP (2001) Cellular delivery of impermeable effector molecules in the form of conjugates with peptides capable of mediating membrane translocation. Bioconjug Chem 12: 825-841. Find this article online
11. Fittipaldi A, Ferrari A, Zoppe M, Arcangeli C, Pellegrini V, et al. (2003) Cell membrane lipid rafts mediate caveolar endocytosis of HIV-1 Tat fusion proteins. J Biol Chem 278: 34141-34149. Find this article online
12. Foster BA, Coffey HA, Morin MJ, Rastinejad F (1999) Pharmacological rescue of mutant p53 conformation and function. Science 286: 2507-2510. Find this article online
13. Fulda S, Wick W, Weller M, Debatin K-M (2002) Smac agonists sensitize for Apo2L/TRAIL- or anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo. Nat Med 8: 808-815. Find this article online
14. Harada H, Hiraoka M, Kizaka-Kondoh S (2002) Antitumor effect of TAT-oxygen-dependent degradation-caspase-3 fusion protein specifically stabilized and activated in hypoxic tumor cells. Cancer Res 62: 2013-2018. Find this article online
15. Hofstra LS, de Vries EGE, Mulder NH, Willemse PHB (2000) Intraperitoneal chemotherapy in ovarian cancer. Cancer Treat Rev 26: 133-143. Find this article online
16. Hupp TR, Sparks A, Lane DP (1995) Small peptides activate the latent sequence-specific DNA binding function of p53. Cell 83: 237-245. Find this article online
17. Kim AL, Raffo AJ, Brandt-Rauf PW, Pincus MR, Monaco R, et al. (1999) Conformational and molecular basis for induction of apoptosis by a p53 C-terminal peptide in human cancer cells. J Biol Chem 274: 34924-34931. Find this article online
18. Lam KS, Zhao Z-G (1997) Targeted therapy for lymphoma with peptides. Hematol Oncol Clin North Am 11: 1007-1019. Find this article online
19. Lindsay MA (2002) Peptide-mediated cell delivery: Application in protein target validation. Curr Opin Pharmacol 2: 587-594. Find this article online
20. Macleod K (2000) Tumor suppressor genes. Curr Opin Genet Dev 10: 81-93. Find this article online
21. McCormick F (2001) Cancer gene therapy: Fringe or cutting edge. Nat Rev Cancer 1: 130-141. Find this article online
22. Nagy JA, Herzberg KT, Dvorak JM, Dvorak HF (1993) Pathogenesis of malignant ascites formation: Initiating events that lead to fluid accumulation. Cancer Res 53: 2631-2643. Find this article online
23. Nagy JA, Masse EM, Herzberg KT, Meyers MS, Yeo K-T, et al. (1995) Pathogenesis of ascites tumor growth: Vascular permeability factor, vascular hyperpermeability, and ascites fluid accumulation. Cancer Res 55: 360-368. Find this article online
24. Parsons SL, Watson SA, Steele RJC (1996) Malignant ascites. Br J Surg 83: 6-14. Find this article online
25. Richard JP, Melikov K, Vives E, Ramos C, Verbeure B, et al. (2002) Cell-penetrating peptides: A reevaluation of the mechanism of cellular uptake. J Biol Chem 278: 585-590. Find this article online
26. Rippin TM, Bykov VJN, Freund SMV, Selivanova G, Wiman KG, et al. (2002) Characterization of the p53-rescue drug CP-31398 in vitro and in living cells. Oncogene 21: 2119-2129. Find this article online
27. Roninson IB, Broude EV, Chang B-D (2002) If not apoptosis, then what?: Treatment-induced senescence and mitotic catastrophe in tumor cells. Drug Resist Updat 4: 303-313. Find this article online
28. Schwarze SR, Ho A, Vocero-Akbani A, Dowdy SF (1999) In vivo protein transduction: Delivery of a biologically active protein into the mouse. Science 285: 1569-1572. Find this article online
29. Selivanova G, Iotsova V, Okan I, Fritsche M, Strom M, et al. (1997) Restoration of the growth suppression function of mutant p53 by a synthetic peptide derived from the p53 C-terminal domain. Nat Med 3: 632-638. Find this article online
30. Selivanova G, Ryabchenko L, Jansson E, Iotsova V, Wiman KG (1998) Reactivation of mutant p53 through interaction of a C-terminal peptide with the core domain. Mol Cell Biol 19: 3395-3402. Find this article online
31. Vousden KH, Lu X (2002) Live or let die: The cell's response to p53. Nat Rev Cancer 2: 594-604. Find this article online
32. Wadia J, Stan R, Dowdy SF (2004) Transducible fusogenic peptide enhances TAT-mediated protein transduction following lipid raft-mediated macropinocytosis. Nature Med In press.